Asset Details
Do you wish to reserve the book?
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
Do you wish to request the book?
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
2018
Overview
Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency. Understanding the relationship between G6PD genotype and the phenotypic expression of the enzyme deficiency is necessary so that severe haemolysis can be avoided. The patterns of oxidative haemolysis have been well described in G6PD deficient hemizygous males and homozygous females; and haemolysis in the proportionally more numerous heterozygous females has been documented mainly following consumption of fava beans and more recently dapsone. It has long been known that 8-aminoquinolines, notably primaquine and tafenoquine, cause acute haemolysis in G6PD deficiency. To support wider use of primaquine in
Plasmodium vivax
elimination, more data are needed on the haemolytic consequences of 8-aminoquinolines in G6PD heterozygous females. Two recent studies (in 2017) have provided precisely such data; and the need has emerged for the development of point of care quantitative testing of G6PD activity. Another priority is exploring alternative 8-aminoquinoline dosing regimens that are practical and improve safety in G6PD deficient individuals.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
Antimalarials - administration & dosage
/ Antimalarials - adverse effects
/ Biomedical and Life Sciences
/ Female
/ Females
/ Glucosephosphate Dehydrogenase Deficiency - complications
/ Glucosephosphate Dehydrogenase Deficiency - genetics
/ Humans
/ Malaria
/ Malaria, Vivax - drug therapy
/ Primaquine - administration & dosage
/ Primaquine - adverse effects
/ Review
